Mechanisms of TNF-alpha Mediated Resolution of Pulmonary Fibrosis
Mechanisms of TNF-alpha Mediated Resolution of Pulmonary Fibrosis
批准号:
9056329
负责人:
Elizabeth Frances Redente
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-04-01 至 2020-03-31
关键词:
AddressAgeAirAnti-Inflammatory AgentsAnti-inflammatoryApoptosisApoptoticArchitectureBiological ModelsBleomycinBone MarrowBurn injuryCaspaseCellsCharacteristicsChimera organismCicatrixClinical TrialsCollagenDevelopmentDiagnosisDiseaseDustEnrollmentFemaleFibroblastsFibrosisGeneral PopulationGeneticGoalsGrowthHamman-Rich syndromeHealthHealthcare SystemsHumanImageIn VitroIncidenceInflammatoryInsulin-Like Growth Factor IInterstitial Lung DiseasesK-Series Research Career ProgramsLiquid substanceLungLung diseasesMarrowMatrix MetalloproteinasesMediatingMediator of activation proteinMilitary PersonnelModelingMolecularMorbidity - disease rateMusMyofibroblastOutcomePathogenesisPathway interactionsPatientsPersonsPhenotypePlatelet-Derived Growth FactorPlayPopulationPopulations at RiskProcessProductionPulmonary FibrosisRehabilitation therapyReporterRepressionResolutionRiskRisk FactorsRoleSmooth Muscle Actin Staining MethodTNF geneTNFRSF1A geneTestingTherapeuticTherapeutic InterventionTimeTissuesTranslatingTranslationsUnited StatesVeteransWorkbasebonecigarette smokingcytokineeffective therapyenvironmental tobacco smoke exposuregenetic manipulationhuman diseasehumanized mousein vivoin vivo Modelmacrophagemalemortalitymouse modelnew therapeutic targetnovelnovel therapeutic interventionnovel therapeuticspollutantprogramspublic health relevanceresearch studyresponserestorationtherapy development
中文摘要
描述(由申请人提供):
英文摘要
DESCRIPTION (provided by applicant):
Project Summary Idiopathic pulmonary fibrosis (IPF) remains a devastating fibrotic parenchymal lung disease with high morbidity and mortality, for which there are no effective therapies. Consequently, it becomes increasingly important to identify molecular pathways that are targetable for therapeutic intervention. This proposal seeks to address this unmet need by investigating the role of TNF- in the resolution of pulmonary fibrosis using the well- characterized bleomycin model in mice. In preliminary studies we have shown that the intratracheal administration of TNF- at the peak of the bleomycin-induced fibrotic response accelerates resolution and that mice with a genetic TNF- deficiency have impaired resolution of fibrosis. These and other considerations have led us to hypothesize that TNF- plays an integral role in the resolution of pulmonary fibrosis through effects on macrophages and myofibroblasts. We hypothesize that TNF- alters the phenotype of both of these cell populations reducing their pro-fibrogenic phenotype and allowing them to aid in the resolution process. Specific aim 1 will address the hypothesis that TNF- induces a switch in macrophage programming from alternative to classical, reducing the production of pro-fibrotic mediators including TGF- and IGF-I, increasing pro-inflammatory cytokine production (TNF-) and enhancing matrix metalloproteinase production to initiate tissue remodeling and the restoration of normal pulmonary architecture. The goal of specific aim 2 is to address the hypothesis that TNF- promotes myofibroblast apoptosis in a two-step process, first by directing myofibroblasts de-differentiation to fibroblasts, and second by sensitizing these fibroblasts to undergo Fas- mediated apoptosis. Finally, specific aim 3 will translate our work into human disease using IPF-derived myofibroblasts and a humanized mouse model of fibrosis. Our proposed studies represent the first time TNF- has been investigated as a key player in the resolution process of pulmonary fibrosis. It also represents a novel opportunity to identify new therapeutic targets for the treatment of IPF. Thus, a long-term goal of this proposal is to translate our anticipated findings into the development of therapies for patients diagnosed with fibrotic lung diseases, including IPF.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Reducing Fibroblast Persistence in Pulmonary Fibrosis as a Mechanism of Resolution
-
批准号:10451554
-
项目类别:
-
资助金额:$54.16万
-
财政年份:2019
-
负责人:Elizabeth Frances Redente
-
依托单位:
Reducing Fibroblast Persistence in Pulmonary Fibrosis as a Mechanism of Resolution
-
批准号:9795882
-
项目类别:
-
资助金额:$52.42万
-
财政年份:2019
-
负责人:Elizabeth Frances Redente
-
依托单位:
Reducing Fibroblast Persistence in Pulmonary Fibrosis as a Mechanism of Resolution
-
批准号:10661572
-
项目类别:
-
资助金额:$54.76万
-
财政年份:2019
-
负责人:Elizabeth Frances Redente
-
依托单位:
Reducing Fibroblast Persistence in Pulmonary Fibrosis as a Mechanism of Resolution
-
批准号:10217236
-
项目类别:
-
资助金额:$53.58万
-
财政年份:2019
-
负责人:Elizabeth Frances Redente
-
依托单位:
The role TNF-alpha and Macrophages in the Resolution of Pulmonary Fibrosis
-
批准号:7752955
-
项目类别:
-
资助金额:$4.72万
-
财政年份:2009
-
负责人:Elizabeth Frances Redente
-
依托单位:
The role TNF-alpha and Macrophages in the Resolution of Pulmonary Fibrosis
-
批准号:8137245
-
项目类别:
-
资助金额:$5.3万
-
财政年份:2009
-
负责人:Elizabeth Frances Redente
-
依托单位:
The role TNF-alpha and Macrophages in the Resolution of Pulmonary Fibrosis
-
批准号:7930529
-
项目类别:
-
资助金额:$5.05万
-
财政年份:2009
-
负责人:Elizabeth Frances Redente
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: